The present invention relates to the provision of pain management in a subject wherein the administration of the composition does not result in any peripherally or supraspinally mediated side effect in the subject. In particular, the present invention relates to the administration of 3-[(1S,2S)-3-(dimethylamino)-1-ethyl-2-methyl-propyl]-phenol in a space that is void of thrombocytes.